Canada will explore new methods to prevent, prepare for and respond to biological threats with a new research contract awarded to ImmunoVaccine Technologies (IVT).
The three-year research agreement was awarded by Defence Research and Development Canada (DRDC).
Go deeper with GlobalData
The contract includes the preclinical application of the company’s DepoVax vaccine for anthrax antigens.
IVT vice president of R&D Dr Marc Mansour said that DepoVax is a very appropriate anti-anthrax vaccine because of the lengthy immunity it provides.
“Dr Les Nagata and his research team at DRDC are leaders in developing vaccines to fight deadly microbial pathogens and we look forward to this collaboration,” Mansour said.
“Because our DepoVax formulation creates a long-lasting immune response and comes in a dry format that is easily reconstituted, it is well suited for the development of an effective anti-anthrax vaccine.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataInfection with anthrax is potentially life-threatening and caused by a spore-forming bacterium, bacillus anthracis.
